Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akari Therapeutics plc filings document the regulatory record of an England and Wales biotechnology issuer whose ordinary shares trade on Nasdaq only in connection with American Depositary Shares. The company’s SEC disclosures cover S-1 registration statements, 8-K material-event reports, proxy materials, and shareholder voting results tied to its ADS and ordinary-share structure.
Akari’s filings describe securities offerings, private placements, warrants, note exchanges, ADS ratio matters, Nasdaq listing-rule approvals, and amendments affecting share capital. Proxy and meeting materials also document U.K. public-company governance, quorum and voting mechanics, security-holder rights, and approvals related to the company’s capital structure.
Akari Therapeutics plc (NASDAQ: AKTX) – Form 4 insider transaction
On 06/20/2025, President & Chief Executive Officer Abizer Gaslightwala, who also serves as a director of the company, purchased 10,000 American Depositary Shares (ADS) of Akari Therapeutics in an open-market transaction. The shares were acquired at a price of $1.20 per ADS, for an aggregate consideration of approximately $12,000.
Following the purchase, the reporting person’s direct holding increased to 271,428 ADS. Each ADS represents 2,000 ordinary shares of Akari Therapeutics with a par value of $0.0001 per ordinary share, as noted in the footnote to the filing.
No dispositions were reported, and the filing shows no derivative security transactions. The form was signed by Torsten Hombeck, acting as attorney-in-fact, on 06/24/2025.
This Form 4 therefore documents a single, straightforward insider purchase by the company’s most senior executive, with no accompanying sales or option exercises disclosed.
Insider Purchase Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has acquired 15,000 American Depositary Shares (ADS) at a price of $1.20 per share on June 17, 2025. Each ADS represents 2,000 ordinary shares of the company.
Following this transaction, Gaslightwala now beneficially owns 261,428 ADSs directly. This insider purchase demonstrates a significant investment by the company's top executive, potentially signaling confidence in the company's future prospects.
- Transaction Type: Direct Purchase (Form 4)
- Total Investment Value: $18,000
- Transaction Date: June 17, 2025
- Filing Date: June 28, 2025
- Ownership Form: Direct